Springer Nature
13395_2019_198_MOESM3_ESM.tif (2.02 MB)

Additional file 3: of Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

Download (2.02 MB)
posted on 2019-05-21, 05:00 authored by Narendra Bharathy, Noah Berlow, Eric Wang, Jinu Abraham, Teagan Settelmeyer, Jody Hooper, Matthew Svalina, Zia Bajwa, Martin Goros, Brian Hernandez, Johannes Wolff, Ranadip Pal, Angela Davies, Arya Ashok, Darnell Bushby, Maria Mancini, Christopher Noakes, Neal Goodwin, Peter Ordentlich, James Keck, Douglas Hawkins, Erin Rudzinski, Atiya Mansoor, Theodore Perkins, Christopher Vakoc, Joel Michalek, Charles Keller
Figure S3. CRISPR/Cas9 mediated HDACs inhibition and evaluation of tumor cell growth inhibition in eRMS. (a-e) CRISPR/Cas9 screen for viability of selected HDACs (HDAC1-2 & HDAC10-11) excision by CRISPR in murine eRMS. (f) Q-PCR of murine eRMS U57810 for the expression of myogenic markers of differentiation in vitro. Data normalized to GAPDH expression. Gene expression was quantified using 2−^dCt method. Myogenin (MYOG), Myoblast determination protein 1 (MyoD) and Myoglobin (Mb). (TIF 2070 kb)


National Institute of Health (US)